ArticleNature communications2025
Rationally designed Fe-cyclopentadienone with unique orientations for efficient asymmetric hydrogenation of acylsilanes.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Fe-cyclopentadienone complexes have been widely utilized in various hydrogenation and dehydrogenation catalytic processes, yet their applications have largely been restricted to non-asymmetric versions. This limitation is primarily due to the considerable challenge of constructing an efficient chiral environment around the active iron center. In this study, we present a structurally distinctive chiral Fe-cyclopentadienone complex with excellent enantiocontrol capabilities. This new iron complex features bulky side arms oriented downward toward the cyclopentadienone plane, which create an ideal chiral environment in front of the catalytically active iron center. It demonstrates excellent performance in the catalytic asymmetric hydrogenation of acylsilanes, exhibiting both high reactivity and selectivity. The broad substrate scope, encompassing aryl-, alkenyl-, and alkyl-acylsilanes, along with successful gram-scale synthesis, underscores its potential applications in pharmaceutical synthesis. Experimental and DFT studies reveal the structural stability and rigidity of the catalyst during catalytic intervals. Additionally, weak interactions between the catalyst and the silyl group in the substrate play a critical role in achieving efficient enantioselectivity. More importantly, this type of chiral iron complex also shows excellent catalytic reactivity and selectivity for asymmetric transfer hydrogenation, utilizing i-PrOH as the hydrogen source.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.